ACTG 175 - Sep., p. 257
Anabolic Steroid Control Act of 1990 - June, p. 171
animal studies - July, p. 203
approvals, diagnostics - July, p. 204
approvals, FDA - Feb., p. 33, 42; Mar., p. 65, 67; Aug., p. 225; Nov., p. 321, 323, 324, 331; Dec., p. 353, 355, 356, 364
approvals, filings - May, p. 129, 139; Aug., p. 227, 228, 236; Sep., p. 264; Oct., p. 292; Nov., p. 330; Dec., p. 357, 364
approvals, Treatment INDs - Sep., p. 260
approvals, U.K. - May, p. 138, 139
blood products - Apr., p. 104, 105; Nov., p. 332
brain bioavailability - Dec., p. 356
canine studies - Aug., p. 236; Dec., p. 360
carcinogenicity - June, p. 171
CD4+ T-cell diagnostics - July, p. 204
clinical trials - Feb., p. 35, 37, 38, 39, 40, 41, 42; Mar., p. 65, 67, 70, 72, 73, 76; Apr., p. 97, 100, 102, 103, 104, 105, 108; May, p. 129, 130, 131, 132, 133, 134, 137, 138, 139, 140; June, p. 162, 164, 165, 168, 169, 170, 171, 172; July, p. 197, 198, 201, 202, 205; Aug., p. 225, 227, 228, 230, 231, 232, 233, 234, 235; Sep., p. 257, 262, 263, 265, 266, 267; Oct., p. 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300; Nov., p. 321, 323, 324, 325, 326, 327, 328, 329, 330, 331; Dec., p. 353, 356, 357, 360, 363, 364
clinical trials, halted - Feb., p. 43; Mar., p. 76; Apr., p. 101
clinical trials, pediatric - Mar., p. 76
Collaborative Research and Development Agreement (CRADAs) - Feb., p. 38, 46; Mar., p. 67; Apr., p. 97, 100, 106, 108; May, p. 135, 136; July, p. 199; Aug., p. 238; Sep., p. 263; Dec., p. 363, 366
Congressional investigations - Feb., p. 42
corporate linkages (see also licensing) - Feb., p. 42; Mar., p. 74, 76; Apr., p. 99, 109; May, p. 134, 135, 136, 140, 142; June, p. 169; July, p. 196; Aug., p. 234; Sep., p. 260, 265, 266, 267; Oct., p. 298; Nov., p. 327, 328, 330, 331; Dec., p. 361, 363
corporate mergers/acquisitions - Mar., p. 71, 75; Apr., p. 98; May, p. 139, 140; July, p. 199; Sep., p. 260, 265; Nov., p. 330, 332; Dec., p. 363
cost-recovery programs - Feb., p. 42
Costa Rica - May, p. 138
Delta trial - Oct., p. 289
drug combinations - July, p. 195; Sep., p. 257
drug usage recommendations - Feb., p. 43
epidemiologic studies - June, p. 171; July, p. 194
expanded access lotteries - June, p. 161, 170; July, p. 203; Aug., p. 233, 235, 236; Oct., p. 298; Dec., p. 364
federal contracts/grants - July, p. 205; Aug., p. 237; Sep., p. 268; Oct., p. 300; Nov., p. 333
funding disagreement - Aug., p. 235
General Agreement on Tariffs and Trade (GATT) - Mar., p. 78
Herpes Management System - Feb., p. 40
HIV diagnostics - Apr., p. 109
HIV in lymph nodes - Nov., p. 328
HIV strains, co-infection - July, p. 203
HIV testing, pregnant women - July, p. 205
HIV-infection, kinetics - Dec., p. 362
HIV-infection, remission - May, p. 131
insurance claims - Sep., p. 266
intermediate trials - June, p. 172
intramural research, NIH - June, p. 172
Japan - May, p. 140
licensing (see also corporate linkages) - Feb., p. 41, 46; Mar., p. 67, 77; Apr., p. 99, 100, 105, 106, 107, 109; May, p. 135, 136, 139, 140, 142; June, p. 168; July, p. 199, 202, 206; Aug., p. 234; Sep., p. 267, 270; Oct., p. 299, 301, 302; Nov., p. 327, 332, 335, 336; Dec., p. 361, 364, 365, 366
licensing opportunities - Apr., p. 109; Aug., p. 238
market size - Nov., p. 332
mitochondrial toxicity - Mar., p. 76
mucosal delivery - Nov., p. 331, 335
mucosal immunity - June, p. 170; Sep., p. 270; Oct., p. 298, 302
new viruses - Feb., p. 38, 44; Mar., p. 77; Apr., p. 103; Sep., p. 263; Oct., p. 294
oligonucleotide synthesis - Feb., p. 41
passive immunization - Feb., p. 40; July, p. 198; Sep., p. 260, 267; Oct., p. 294
patent claims, clinical utility - Feb., p. 45
patent disputes - Feb., p. 42, 44, 45, 46; Apr., p. 105, 109; May, p. 141; June, p. 173; Sep., p. 269, 279; Nov., p. 334, 335; Dec., p. 366
Points to Consider documents - Sep., p. 267
primate studies - May, p. 133; July, p. 194; Oct., p. 295; Nov., p. 325, 331; Dec., p. 361
reasonable pricing (licensing) - Apr., p. 106
rejections, FDA - Mar., p. 75
resistance, HIV protease inhibitors - July, p. 195
rodent models, hepatitis - Sep., p. 265
rodent studies - Oct., p. 298
screening - Feb., p. 41; Apr., p. 103, 109; May, p. 136, 140; June, p. 172; July, p. 202; Aug., p. 238; Sep., p. 265; Oct., p. 300; Nov., p. 335
Sexually Transmitted Diseases Cooperative Res. Centers - Sep., p. 268
South Korea - Feb., p. 41
spermicides - May, p. 137
synthesis difficulties - Mar., p. 72
Taiwan - Feb., p. 41
TH1 cellular immune responses - July, p. 200
Thailand - May, p. 139
thymidine kinase gene insertion - Feb., p. 42
transgenic animals - Sep., p. 267; Nov., p. 336
translation inhibition - Feb., p. 41
Treatment IND - Feb., p. 42
triple helix structures - June, p. 171
universal vaccination - July, p. 204
veterinary vaccines - Oct., p. 301
virology Web pages - Sep., p. 269
viruses, oncogenic - June, p. 163
yeast expression system - June, p. 171; Oct., p. 302; Dec., p. 364
Zaire - Sep., p. 267